• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The PID Odyssey 2030: outlooks, unmet needs, hurdles, and opportunities - proceedings from the IPOPI global multi-stakeholders' summit (June 2022).PID 奥德赛 2030:展望、未满足的需求、障碍和机遇——来自 IPOPI 全球利益相关者峰会(2022 年 6 月)的会议记录。
Front Immunol. 2023 Aug 15;14:1245718. doi: 10.3389/fimmu.2023.1245718. eCollection 2023.
2
Charting a course for global progress in PIDs by 2030 - proceedings from the IPOPI global multi-stakeholders' summit (September 2023).绘制到 2030 年全球 PID 进展的路线图——来自 IPOPI 全球利益相关者峰会的会议记录(2023 年 9 月)。
Front Immunol. 2024 Jun 27;15:1430678. doi: 10.3389/fimmu.2024.1430678. eCollection 2024.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
The PID Principles of Care: Where Are We Now? A Global Status Report Based on the PID Life Index.PID 关爱原则:我们现在处于何处?基于 PID 生活指数的全球现状报告。
Front Immunol. 2021 Nov 18;12:780140. doi: 10.3389/fimmu.2021.780140. eCollection 2021.
6
7
The PID Life Index: an interactive tool to measure the status of the PID healthcare environment in any given country.PID 生命指数:一个互动工具,可衡量任何给定国家的 PID 医疗保健环境的状况。
Orphanet J Rare Dis. 2022 Jan 8;17(1):11. doi: 10.1186/s13023-021-02161-0.
8
Newborn Screening Today and Tomorrow: A Brief Report from the International Primary Immunodeficiencies Congress.新生儿筛查的现状与未来:国际原发性免疫缺陷大会简要报告
Int J Neonatal Screen. 2024 Apr 5;10(2):30. doi: 10.3390/ijns10020030.
9
The First National Pain Medicine Summit--final summary report.第一届全国疼痛医学峰会——最终总结报告。
Pain Med. 2010 Oct;11(10):1447-68. doi: 10.1111/j.1526-4637.2010.00961.x.
10
Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency Diseases: Current Status and Future Perspectives.原发性免疫缺陷病中的造血干细胞移植:现状与未来展望
Front Pediatr. 2019 Aug 8;7:295. doi: 10.3389/fped.2019.00295. eCollection 2019.

引用本文的文献

1
Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years.应对原发性免疫缺陷病领域的变革:把握未来十年的机遇并预见威胁
Front Immunol. 2025 Jun 17;16:1596971. doi: 10.3389/fimmu.2025.1596971. eCollection 2025.
2
Charting a course for global progress in PIDs by 2030 - proceedings from the IPOPI global multi-stakeholders' summit (September 2023).绘制到 2030 年全球 PID 进展的路线图——来自 IPOPI 全球利益相关者峰会的会议记录(2023 年 9 月)。
Front Immunol. 2024 Jun 27;15:1430678. doi: 10.3389/fimmu.2024.1430678. eCollection 2024.
3
Newborn Screening Today and Tomorrow: A Brief Report from the International Primary Immunodeficiencies Congress.新生儿筛查的现状与未来:国际原发性免疫缺陷大会简要报告
Int J Neonatal Screen. 2024 Apr 5;10(2):30. doi: 10.3390/ijns10020030.
4
Pandemic effects on the care of patients with inborn errors of immunity.大流行对免疫缺陷病患者护理的影响。
Asia Pac Allergy. 2023 Sep;13(3):95-96. doi: 10.5415/apallergy.0000000000000117. Epub 2023 Sep 11.

本文引用的文献

1
Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.人类先天性免疫缺陷:国际免疫学联盟专家委员会 2022 年更新的分类。
J Clin Immunol. 2022 Oct;42(7):1473-1507. doi: 10.1007/s10875-022-01289-3. Epub 2022 Jun 24.
2
Quality of Life and Social and Psychological Outcomes in Adulthood Following Allogeneic HSCT in Childhood for Inborn Errors of Immunity.儿童先天性免疫缺陷异基因 HSCT 后成年期生活质量和社会心理结局
J Clin Immunol. 2022 Oct;42(7):1451-1460. doi: 10.1007/s10875-022-01286-6. Epub 2022 Jun 20.
3
A pilot study of assessing whole genome sequencing in newborn screening in unselected children in China.一项在中国未筛选儿童中评估新生儿筛查全基因组测序的试点研究。
Clin Transl Med. 2022 Jun;12(6):e843. doi: 10.1002/ctm2.843.
4
Towards Achieving Equity and Innovation in Newborn Screening across Europe.迈向欧洲新生儿筛查的公平与创新。
Int J Neonatal Screen. 2022 May 6;8(2):31. doi: 10.3390/ijns8020031.
5
Retrospective, Landmark Analysis of Long-term Adult Morbidity Following Allogeneic HSCT for Inborn Errors of Immunity in Infancy and Childhood.婴儿和儿童时期异基因 HSCT 治疗先天性免疫缺陷的长期成人发病率的回顾性标志性分析。
J Clin Immunol. 2022 Aug;42(6):1230-1243. doi: 10.1007/s10875-022-01278-6. Epub 2022 May 17.
6
Newborn screening as a fully integrated system to stimulate equity in neonatal screening in Europe.新生儿筛查作为一个全面整合的系统,以促进欧洲新生儿筛查的公平性。
Lancet Reg Health Eur. 2022 Jan 28;13:100311. doi: 10.1016/j.lanepe.2022.100311. eCollection 2022 Feb.
7
An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years.原发性免疫缺陷中非感染性表现的频率和严重程度评估:一项对超过 10 年的 1375 例患者的全国回顾性队列研究。
J Allergy Clin Immunol. 2022 Jun;149(6):2116-2125. doi: 10.1016/j.jaci.2021.12.790. Epub 2022 Jan 12.
8
The PID Principles of Care: Where Are We Now? A Global Status Report Based on the PID Life Index.PID 关爱原则:我们现在处于何处?基于 PID 生活指数的全球现状报告。
Front Immunol. 2021 Nov 18;12:780140. doi: 10.3389/fimmu.2021.780140. eCollection 2021.
9
Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.JAK 抑制剂在治疗先天性免疫缺陷中的新地位。
Front Immunol. 2021 Sep 17;12:717388. doi: 10.3389/fimmu.2021.717388. eCollection 2021.
10
How I use allogeneic HSCT for adults with inborn errors of immunity.我如何使用异基因 HSCT 治疗成人先天性免疫缺陷。
Blood. 2021 Nov 4;138(18):1666-1676. doi: 10.1182/blood.2020008187.

PID 奥德赛 2030:展望、未满足的需求、障碍和机遇——来自 IPOPI 全球利益相关者峰会(2022 年 6 月)的会议记录。

The PID Odyssey 2030: outlooks, unmet needs, hurdles, and opportunities - proceedings from the IPOPI global multi-stakeholders' summit (June 2022).

机构信息

Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom.

IPOPI, Brussels, Belgium.

出版信息

Front Immunol. 2023 Aug 15;14:1245718. doi: 10.3389/fimmu.2023.1245718. eCollection 2023.

DOI:10.3389/fimmu.2023.1245718
PMID:
37654496
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10465327/
Abstract

IPOPI held its first Global Multi-Stakeholders' Summit on 23-24 June 2022 in Cascais, Portugal. This IPOPI initiative was designed to set the stage for a stimulating forward-thinking meeting and brainstorming discussion among stakeholders on the future priorities of the PID community. All participants were actively engaged in the entire Summit, bringing provocative questions to ensure a high level of discussion and engagement, and partnered in identifying the outlooks, unmet needs, hurdles and opportunities of PIDs for 2030. The topics that were covered include diagnosis (e.g., newborn screening [NBS], genomic sequencing- including ethical aspects on the application of genomics on NBS, the role of more accurate and timely diagnostics in impacting personalized management), treatment (e.g., the therapeutic evolution of immunoglobulins in a global environment, new therapies such as targeted therapies, new approaches in curative therapies), the interactions of Primary ID with Secondary ID, Autoinflammatory Diseases and other diseases as the field experiences an incessant evolution, and also the avenues for research in the field of humanities and human sciences such as Patient-Reported Outcome Measures (PROMs), Patient-Reported Experience Measures (PREMs), and Health-Related Quality Of Life (HRQoL). During this meeting, all participants contributed to the drafting of recommendations based on our common understanding of the future opportunities, challenges, and scenarios. As a collection of materials, perspectives and summaries, they are succinct and impactful and may help determine some of the next key steps for the PID community.

摘要

国际PID 组织于 2022 年 6 月 23 日至 24 日在葡萄牙卡斯卡伊斯举办了首届全球利益攸关方峰会。此次 IPOPI 会议旨在为利益攸关方就 PID 社区的未来重点进行富有启发性的前瞻性会议和头脑风暴讨论奠定基础。所有与会者都积极参与了整个峰会,提出了发人深省的问题,以确保讨论和参与度达到较高水平,并合作确定了 2030 年 PID 的前景、未满足的需求、障碍和机遇。会议涵盖的主题包括诊断(例如,新生儿筛查[NBS],基因组测序——包括基因组学在 NBS 应用方面的伦理问题,更准确和及时的诊断在影响个性化管理方面的作用)、治疗(例如,在全球环境中免疫球蛋白的治疗演变,新疗法如靶向疗法,治疗性疗法的新方法)、原发性 ID 与继发性 ID、自身炎症性疾病和其他疾病的相互作用,因为该领域正在经历持续的演变,以及人文科学和人类科学领域的研究途径,如患者报告的结果测量(PROMs)、患者报告的体验测量(PREMs)和健康相关生活质量(HRQoL)。在这次会议上,所有参与者都根据我们对未来机遇、挑战和情况的共同理解,为起草建议做出了贡献。作为一系列材料、观点和摘要,它们简洁而有力,可能有助于确定 PID 社区的一些下一个关键步骤。